Tempus, one of Chicago’s top ten health techs focusing on building the world’s largest library of molecular and clinical data, paired up with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center in a new research collaboration that will focus on identifying cancer patients that respond favorably to what is regarded the next generation of cancer care, namely immunotherapy treatment. This collaboration is considered to be part of the value-based care trend that relies on precise classification if illness and smarter use of data to advance clinical outcomes and reduce cancer-care costs.
Immunotherapy is grouped under the broad area of precision medicine, a system that considers the type of cancer, a person’s genetic makeup and other factors to customize cancer care with the best outcomes and the least side effects. It is defined as a therapy that stimulates a patient’s immune system to fend off diseases such as cancer by working harder or smarter to attack cancer cells. This therapy is part of the broader strategy of precision medicine, which takes into account the type of cancer, a person’s genetic makeup and other factors to tailor treatment for the best outcomes.
“In oncology, datasets have been small and disorganized, making it impossible to realize the promise of precision medicine,” said Eric Lefkofsky, Founder and CEO at Tempus. “Tempus has spent the last two years building a series of data pipelines to collect, cleanse, and analyze data, at scale, to support the efforts of physicians and researchers on the frontlines of care.”
Tempus collects patients’ DNA and RNA samples for sequencing and uses molecular science and Big Data analytics to build “the world’s largest library of clinical and molecular data to personalize and improve cancer care.” It pairs that with patients’ health and treatment histories to help health care personnel take a more personal and customized treatment approach. Tempus’ immunotherapy, regarded as one of the most comprehensive immunology platforms available, is driven by a state of the art integrative molecular profiling approach that relies on DNA and RNA data and immunohistochemistry and TCR sequencing. It allows physicians access to molecular data such as specific gene alterations and mutational burden as well as immune infiltration, HLA type, neoantigen predictions, and immunotherapy targets.
According to Andre Goy, M.D., chairman and director, John Theurer Cancer Center “This exciting venture is the perfect union of the best in technology and the most promising breakthroughs in cancer treatment.’’ “It allows us to apply precision medicine to the booming field of immunotherapy enhancing our ability to provide patients with the best care possible,’’ he added.
“Immunotherapy treatment has shown great promise; however, not everyone with cancer is an ideal candidate,” said Martin E. Gutierrez M.D., director of the Drug Discovery and Phase 1 Unit at John Theurer Cancer Center. “Our collaboration with Tempus will support physicians’ work to determine whether this treatment is right for their patients.”
“It’s critical to develop tools that allow oncologists to determine if a patient will benefit from immunotherapy for their specific tumor and this collaborative project gets us closer to that goal,” said Giuseppe Giaccone, M.D., Ph.D., associate director for clinical research at Georgetown Lombardi. “We want to make sure patients are offered the best treatment options from the start, so we don’t lose time and patients avoid potential side effects of treatments as well as unnecessary expenses of therapies that don’t benefit them.”
The Tempus platform offers both physicians and patients the world’s largest library of clinical and molecular data to personalize and improve cancer care. The company has also partnered with the Mayo Clinic, the University of Michigan, the Cleveland Clinic, Duke University School of Medicine, the UC Davis Comprehensive Cancer Center, Knight Cancer Institute at the OHSU and Northwestern’s Lurie Comprehensive Cancer Center.
Tempus provides DNA/RNA genomic sequencing services molecular and therapeutic data analysis and as such offers an interactive and analytical machine learning platform through which it enables physicians to deliver personalized cancer care for patients. The company’s goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as Tempus gathers more data. For more information, visit tempus.com, “Tempus Labs” on Facebook and @TempusLabs on Twitter. For more information on Eric Lefkofsky, visit lefkofsky.com.